Therefore, the strategies aimed to recover the expression of WASP, which are currently being tested for WAS patients,58 may be potentially considered as a therapeutic approach for some CML patients. This evidence concerns the gene WAS and chronic myelogenous leukemia, BCR-ABL1 positive.